SXTP.NASDAQ60 Degrees Pharmaceuticals, INC

S-1: 60 Degrees Pharmaceuticals Launches Public Offering Amidst Going Concern Doubts, Eyes Expansion in Infectious Disease Market

Sentiment:

Registration Statement 7 July 2025 5:23 PM

📋All filings for 60 Degrees Pharmaceuticals, INC

60 Degrees Pharmaceuticals, Inc. has filed an S-1 registration statement for a public offering of common stock and warrants to raise approximately $4.2 million, while its auditors have raised substantial doubt about its ability to continue as a going concern.

Delay expectedThe company requested FDA authorization to import Kodatef from Australia due to robust demand for Arakoda in late 2024/early 2025 and the potential for delays in the completion of new lots of Arakoda by its key supplier, PCI.The FDA-mandated malaria prophylaxis study in pediatric and adolescent subjects cannot be initiated any earlier than the third quarter of 2026 due to the time periods required to secure protocol approvals from the FDA and Ethics Committees.

Capital raiseThe company is conducting a public offering of up to 2,036,659 shares of common stock and accompanying warrants, with estimated net proceeds of approximately $4,181,431.In February 2025, the company completed a registered direct offering, selling 300,700 shares of common stock at $3.575 per share, raising net proceeds of $908,627.In January 2025, the company completed another registered direct offering, selling 204,312 shares of common stock at $5.105 per share, raising net proceeds of approximately $804,346.From July 19, 2024, to August 2, 2024, the company sold 135,568 shares in an At-the-Market (ATM) Offering for gross proceeds of $1,994,583.The company's independent auditors have raised substantial doubt about its ability to continue as a going concern, indicating that additional capital will be required to fund operations and business plans.

Worse than expectedIndependent auditors have issued a report raising substantial doubt about the company's ability to continue as a going concern, indicating a precarious financial position.The current offering is a 'best-efforts' offering with no minimum amount of securities required to be sold, meaning there is no guarantee the company will raise the necessary capital to fund its operations and business goals.The offering will result in immediate and substantial dilution to existing stockholders, and further dilution is expected from future capital raises, which are anticipated to be necessary.The Warrants and Pre-Funded Warrants being offered will not have an established public trading market, limiting their liquidity for investors.

Summary

60 Degrees Pharmaceuticals, Inc. is offering up to 2,036,659 shares of common stock, along with Series A-1 and Series A-2 warrants to purchase an equal number of shares, at a combined assumed public offering price of $2.455 per unit.
The company may also offer Pre-Funded Warrants to purchasers whose beneficial ownership would exceed 4.99% (or 9.99% at election) of outstanding common stock, with an exercise price of $0.0001 per share.
Estimated net proceeds from this offering are approximately $4,181,431, intended for general corporate purposes, including working capital.
The company's independent auditors have issued a report raising substantial doubt about its ability to continue as a going concern, indicating a need for additional capital.
Arakoda, the company's FDA-approved malaria preventative, entered the U.S. supply chain in Q3 2019, and recent market research suggests prescribing for malaria prevention has returned to pre-pandemic levels, with an estimated accessible market for Arakoda of about 330,000 prescriptions.
The company is repositioning Tafenoquine (the active ingredient in Arakoda) for new indications, including treatment of Chronic Babesiosis (estimated potential market of up to 380,000 individuals annually, representing approximately $245 million in sales), Acute Babesiosis (up to 38,000 cases annually), prevention of tick-borne diseases, and veterinary indications.
Tafenoquine is also being explored for treatment of Candida infections (50,000 reported cases annually in the U.S.) and prevention of fungal pneumonias (91,000-92,000 new patient cases annually).
Celgosivir, another potential clinical candidate, shows activity in animal models for viral diseases like Dengue and RSV.
The company completed a pilot study of Tafenoquine for canine babesiosis and is exploring botanical extracts from Australian Chestnut trees (Castanospermine) for antiviral, metabolic, and immunomodulatory effects.
A 1-for-5 reverse stock split of common stock was effected on February 24, 2025.
As of July 2, 2025, there were 1,472,891 shares of common stock issued and outstanding.
The company's actual cash, cash equivalents, and short-term investments were $3,451,500 as of March 31, 2025, with total stockholders' equity of $4,028,889.
The offering is a 'best-efforts' basis, meaning there is no minimum amount of securities required to be sold, and the company may not raise the full amount of capital sought.
The Warrants and Pre-Funded Warrants will not be listed on any national securities exchange, limiting their liquidity.

Sentiment

Score: 4

Explanation: The company presents promising drug candidates and strategic market expansion plans, particularly for Tafenoquine. However, the explicit 'going concern' warning from auditors, the 'best-efforts' nature of the offering with no guaranteed minimum raise, and the significant dilution for existing shareholders indicate a high level of financial risk and uncertainty that overshadows the positive scientific and commercial developments.

Positives

Arakoda, the company's malaria preventative, is FDA and TGA approved, offering convenient weekly dosing, no reported drug resistance, and activity against all malaria species and drug-resistant strains.
The company is actively repositioning Tafenoquine for significant market opportunities in tick-borne diseases (Babesiosis) and fungal infections, with promising preclinical and case series data.
Recent sales growth for Arakoda is attributed to organic growth from prescribing by Lyme community physicians for Chronic Babesiosis.
The company has a competitive strength in achieving clinical milestones inexpensively through productive research partnerships with public and academic entities.
Celgosivir and Castanospermine show potential for broad antiviral, metabolic, and immunomodulatory effects, with ongoing non-clinical studies.
FDA authorized the importation of Kodatef from Australia to mitigate potential supply disruptions of Arakoda in the U.S. market, demonstrating proactive supply chain management.
The company has secured exclusive worldwide licenses for key intellectual property related to Tafenoquine for malaria and babesiosis, and Celgosivir for Dengue and other viral diseases.

Negatives

Independent auditors have issued a report raising substantial doubt about the company's ability to continue as a going concern, indicating a critical need for additional capital.
The current offering is on a 'best-efforts' basis with no minimum amount of securities required to be sold, meaning the company may not raise the capital it believes is required for its business plans.
The Warrants and Pre-Funded Warrants offered will not have an established public trading market, limiting their liquidity.
The exercise of Warrants is contingent on stockholder approval, which is not guaranteed, potentially rendering them valueless.
The company expects significant dilution for existing stockholders from the current offering and anticipates further dilution from future equity offerings.
The company has not generated sufficient revenues to fund operations and will require additional financing in the foreseeable future.
Arakoda faces barriers to entry in the malaria prevention market, including low brand awareness and competition from cheaper generic alternatives.
The company has not paid dividends in the past and does not anticipate paying any in the foreseeable future, limiting investor returns to stock appreciation.

Risks

The offering is a best-efforts offering with no minimum amount of securities required to be sold, meaning the company may not raise the amount of capital it believes is required for its business plans.
The Warrants are speculative in nature and do not confer common stock ownership rights until exercised.
There is no public market for the Pre-Funded Warrants or Warrants, limiting their liquidity.
In a bankruptcy or reorganization proceeding, unexercised warrants may be held as executory contracts subject to rejection, potentially rendering them valueless.
Provisions of the Warrants could discourage an acquisition of the company by a third-party.
If the company does not maintain a current and effective prospectus for common stock issuable upon warrant exercise, holders may only be able to exercise on a cashless basis, resulting in fewer shares.
The issuance of Warrants may adversely affect the market price of common stock and make it more difficult to effect a business combination.
The exercise of Warrants will increase the number of issued and outstanding shares, leading to dilution for existing stockholders.
The company will not receive any meaningful additional funds upon the exercise of Pre-Funded Warrants, as the aggregate exercise price was largely pre-funded.
The Warrants are not exercisable until Warrant Stockholder Approval, which is not guaranteed, potentially rendering them valueless.
The company will require additional financing in the future to continue as a going concern, regardless of the proceeds from this offering.
Management has broad discretion in the use of net proceeds from this offering, which may not be used effectively to increase investment value.
The price of the company's common stock may be volatile, and investors may be unable to resell shares at or above the offering price.
The company may not be able to maintain the listing of its common stock on Nasdaq, which could adversely affect liquidity and trading volume.
A possible short squeeze due to sudden demand exceeding supply may lead to price volatility unrelated to company performance.
The company has an FDA post-marketing requirement to conduct a malaria prophylaxis study in pediatric and adolescent subjects, which is estimated to cost $2 million and cannot be initiated before Q3 2026.

Future Outlook

The company intends to use the proceeds from the current offering for general corporate purposes, including working capital, and anticipates requiring additional capital to continue as a going concern and expand operations. It plans to conduct clinical trials to expand Tafenoquine's use for new indications, with results from babesiosis studies potentially available in Q1 2026, aiming for marketing approval for babesiosis. The company also expects to evaluate Celgosivir in additional non-clinical disease models before deciding on clinical development and will assess the technical and commercial feasibility of developing botanical extracts of Australian Chestnut trees.

Management Comments

"Tafenoquine is going to make a huge difference, I think, in people who are severely immunocompromised." (Paraphrased from investigators in a recently published case series on Tafenoquine for babesiosis, cited by the company).
"Our main competitive strength has been our ability to achieve important clinical milestones inexpensively in therapeutic areas that other entities have found extremely challenging." (From 'Competitive Strengths' section).
"We plan to focus in the future on generating proof of concept clinical data sets for the approved Arakoda regimen of Tafenoquine in other therapeutic areas, all of which is expected to foster and continue our existing tradition of inexpensive product development." (From 'Competitive Strengths' section).
"We believe, if the Company does not become capital-limited, and no recruitment issues are encountered, that the results of one or more of the above studies will come to fruition in the first quarter of 2026, potentially facilitating submission of a supplementary new drug application (or other appropriate regulatory filing) to FDA, with the goal of obtaining marketing approval of Arakoda for treatment of Babesiosis." (From 'Development of the Arakoda Regimen of Tafenoquine for Babesiosis' section).

Industry Context

The company operates in the specialty pharmaceutical sector, focusing on infectious diseases, a field with ongoing unmet medical needs. Its strategy of repositioning existing drugs with known safety profiles (like Tafenoquine) for new indications is a common industry approach to reduce development costs and risks. The focus on tick-borne diseases like Babesiosis aligns with increasing public health concerns and reported caseloads in endemic areas. The exploration of broad-spectrum antifungals and antivirals addresses growing challenges of drug resistance and emerging viral threats. The company's reliance on partnerships with public and academic entities for research and development is a recognized model for smaller biotech firms to leverage external expertise and funding.

Comparison to Industry Standards

Arakoda's convenient once-weekly dosing regimen for malaria prevention is noted as a feature superior to some generic alternatives like atovaquone-proguanil, which typically requires daily dosing.
The estimated accessible market for Arakoda in malaria prevention (approximately 330,000 prescriptions annually) is about one-third of the total U.S. market (1.1 million prescriptions), indicating a significant but not dominant market share compared to established competitors like Malarone and generic atovaquone-proguanil.
The estimated potential market for Tafenoquine in persistent babesiosis (up to 380,000 individuals annually, $245 million in sales) represents a substantial growth opportunity, mirroring the historical shift in Lyme disease case estimates from <30,000 to >475,000, suggesting a potential for significant market expansion if FDA labeling is achieved.
Tafenoquine's potential as a treatment for acute babesiosis, particularly in immunosuppressed patients, is highlighted by a case series showing 80% cure rates in patients who failed conventional antibiotics, suggesting a potentially superior outcome compared to standard multi-week regimens of atovaquone and azithromycin.
For canine babesiosis, Tafenoquine's estimated treatment cost of less than $300 per course is presented as a compelling alternative to the standard of care (atovaquone and azithromycin), which costs about $1,350 out of pocket, indicating a significant cost advantage.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Commercial Officer	NA	Kristen Landon	February 2024	Hired to lead commercial efforts for Arakoda reintroduction and new product planning for babesiosis.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Reverse Stock Split	Effected a reverse stock split of common stock at a ratio of 1-for-5.	February 24, 2025	Adjusted financial information, share numbers, option numbers, warrant numbers, other derivative security numbers and exercise prices to reflect the split.
Authorized Capital Stock	Authorized to issue 151,000,000 shares of capital stock, comprising 150,000,000 common stock ($0.0001 par value) and 1,000,000 blank check Series A Preferred Stock. These shares are available for future issuance without stockholder approval.	NA	Provides flexibility for future public offerings, corporate acquisitions, dividends, or equity compensation, but also enables the Board to issue shares to friendly parties or preferred stock with terms that could deter takeovers, potentially diluting existing common stockholders' voting power and distribution rights.
Shareholder Approval for Warrants	Warrants are not exercisable until the effective date of stockholder approval of the issuance of shares upon exercise of the Warrants, unless Pricing Conditions are met.	NA	Introduces a contingency for warrant exercise, potentially delaying the full realization of capital from the offering and creating uncertainty for warrant holders if approval is not obtained.

Legal Proceedings

No action, suit, inquiry, notice of violation, proceeding or investigation pending or threatened against or affecting the company or any subsidiary that would individually or in the aggregate result in a Material Adverse Effect.
No Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty against the company, any subsidiary, or any director or officer.
No pending or contemplated investigation by the Commission involving the company or any current or former director or officer.
The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the company or any subsidiary.

Related Party Transactions

On July 11, 2023, 175 shares of common stock were issued to Geoffrey S. Dow Revocable Trust from the conversion of a Convertible Promissory Note dated May 19, 2022.
On July 11, 2023, 874 shares of common stock were issued to Walleye Opportunities Master Fund Ltd. from the conversion of a Convertible Promissory Note dated May 24, 2022.
On July 11, 2023, 1,049 shares of common stock were issued to Bigger Capital Fund, LP from the conversion of a Convertible Promissory Note dated May 24, 2022.
On July 11, 2023, 874 shares of common stock were issued to Cavalry Investment Fund, LP. from the conversion of a Convertible Promissory Note dated May 24, 2022.
On July 11, 2023, 350 shares of common stock were issued to Cyberbahn Federal Solutions, LLC. from the conversion of a Convertible Promissory Note dated May 8, 2023.
On July 11, 2023, 350 shares of common stock were issued to Ariana Bakery Inc from the conversion of a Convertible Promissory Note dated May 8, 2023.
On July 11, 2023, 1,049 shares of common stock were issued to Sabby Volatility Warrant Master Fund, Ltd. from the conversion of a Convertible Promissory Note dated May 8, 2023.
On July 11, 2023, 175 shares of common stock were issued to Steel Anderson from the conversion of a Convertible Promissory Note dated May 8, 2023.
On July 11, 2023, 350 shares of common stock were issued to Bixi Gao & Ling Ling Wang from the conversion of a Convertible Promissory Note dated May 8, 2023.
On July 11, 2023, a total of 668 restricted shares of common stock were issued to directors Stephen Toovey (167), Charles Allen (167), Paul Field (167), and Cheryl Xu (167).
On July 14, 2023, 488 restricted shares of common stock were issued to BioIntelect Pty Ltd as deferred equity compensation valued at $155,000.
On July 14, 2023, 3,583 shares of common stock were issued to Xu Yu upon conversion of debt.
On July 14, 2023, 18,473 shares of common stock were issued to Knight Therapeutics (Barbados) Inc. upon conversion of debt.
On July 14, 2023, 80,965 shares of Series A Preferred Stock were issued to Knight Therapeutics (Barbados) Inc. from the conversion of accumulated interest from debt.
On July 28, 2023, 760 restricted shares of common stock were issued to Knight Therapeutics (Barbados) Inc. upon conversion of 2,162 shares of Series A Preferred Stock.
The company pays Knight Therapeutics Inc. a royalty equal to 3.5% of net sales until July 12, 2033, or full conversion/redemption of Series A Preferred Stock owned by Knight.
Sichenzia Ross Ference Carmel LLP, the company's counsel, was issued 1,667 shares of common stock in the company's initial public offering.

Stakeholder Impact

**Shareholders**: Existing shareholders will experience immediate and substantial dilution from the current offering. The 'best-efforts' nature of the offering and the 'going concern' warning introduce significant financial risk. No dividends are expected, meaning returns are solely dependent on stock price appreciation.
**Employees**: The company continues to grant equity compensation (options) to key personnel, aligning their interests with company performance.
**Customers**: Potential for new and improved treatment options for infectious diseases, particularly for babesiosis and fungal infections, could lead to better patient outcomes and more convenient dosing regimens.
**Suppliers**: The company maintains quality and contract manufacturing agreements with key suppliers like Piramal Enterprises Limited and PCI Pharma Services, indicating ongoing business relationships. However, potential supply delays (as seen with Arakoda) could impact product availability.
**Creditors**: The 'going concern' warning from auditors indicates increased risk for creditors, as the company's ability to meet its obligations is in doubt without additional capital.

Next Steps

Complete the current public offering of common stock and warrants.
Seek Warrant Stockholder Approval for the exercise of Warrants, if needed, promptly and no later than 90 days after the offering's consummation, and call subsequent meetings every 90 days until approval is obtained or Warrants are no longer outstanding.
Utilize net proceeds from the offering for general corporate purposes, including working capital.
Continue the ARAKODA commercial pilot program to increase awareness, drive trial and usage, and facilitate access and affordability for malaria prevention.
Conduct three planned clinical trials for Tafenoquine in Babesiosis (Trial 1: randomized, placebo-controlled in hospitalized patients; Trial 2: expanded use study for persistent babesiosis; Trial 3: Phase II open label study for chronic babesiosis).
Generate additional prospective data from Trial 2 to confirm Tafenoquine's activity in immunocompromised patients with relapsing babesiosis.
Ascertain whether Arakoda treatment improves patient-reported fatigue symptoms in individuals with chronic babesiosis in Trial 3.
Conduct a gap analysis for the canine babesiosis pilot study to determine additional work required for Minor Use/Minor Species (MUMS) designation and conditional marketing approval.
Complete animal studies of single-dose parenteral administration of Tafenoquine for efficacy against Candida spp by Q2 2025.
Evaluate Celgosivir in additional non-clinical disease models before making a decision regarding clinical development for viral diseases.
Assess the technical and commercial feasibility of developing botanical extracts of Australian Chestnut trees as a complementary approach to Celgosivir.
Propose an alternate design for the FDA-mandated pediatric and adolescent malaria prophylaxis study, with initiation no earlier than Q3 2026.
Maintain listing of common stock on The Nasdaq Capital Market and apply to list all Shares and Warrant Shares on such Trading Market.

Key Dates

Date	Description
2013-12-03	60P Australia Pty Ltd was formed and registered in Queensland.
2014	Entered into a cooperative research and development agreement with the United States Army to complete development of Arakoda for malaria prevention.
2018	FDA approved Arakoda for malaria prevention in individuals 18 years and older.
2018	Australia's Therapeutic Goods Administration (TGA) approved Kodatef for prevention of malaria in travelers.
2019-09-01	Arakoda entered the U.S. supply chain in the third quarter.
2019-09-01	Tafenoquine entered the commercial supply chains in Australia in the third quarter.
2021-02-15	Entered into the Inter-Institutional Agreement with FSURF, granting FSURF the right to manage licensing of certain intellectual property (term expires five years from this date).
2021-02-19	Entered into an Option Agreement with FSURF, subsequently amended on February 15, 2023, for castanospermine purification and COVID-19 treatment (effective through August 19, 2024).
2021-08-19	Entered into an Option Agreement with FSURF, subsequently amended on February 15, 2023, for alpha glucosidase inhibitors and Zika treatment (effective through August 19, 2024).
2022-06-01	60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware, and 60 Degrees Pharmaceuticals, LLC merged into it.
2022-06-01	60P Singapore Pte. Ltd. dissolved in the second quarter.
2022-11-28	Board of Directors Agreement dated with Charles Allen and Stephen Toovey.
2022-12-09	Board of Directors Agreement dated with Cheryl Xu.
2022-12-15	Board of Directors Agreement dated with Paul Field.
2023-01-12	Employment Agreements dated with Geoffrey Dow and Tyrone Miller.
2023-07-11	Conversion of Convertible Promissory Notes (Dow Note, Walleye Note, Bigger Capital Fund Note, Cavalry Investment Fund Note, Cyberbahn Note, Ariana Note, Sabby Note, Anderson Note, Gao & Wang Note) into common stock.
2023-07-11	Issued 668 restricted shares of common stock to directors Stephen Toovey, Charles Allen, Paul Field, and Cheryl Xu.
2023-07-11	Granted 632 fully vested, non-qualified options to directors Stephen Toovey, Charles Allen, Paul Field, and Cheryl Xu at an exercise price of $318.00 per share.
2023-07-14	Issued 488 restricted shares of common stock to BioIntelect Pty Ltd as deferred equity compensation.
2023-07-14	Converted debt owed to Xu Yu into 3,583 shares of common stock.
2023-07-14	Issued 18,473 shares of common stock to Knight Therapeutics (Barbados) Inc. upon conversion of debt.
2023-07-14	Converted accumulated interest from debt owed to Knight into 80,965 shares of Series A Preferred Stock.
2023-07-28	Issued 760 restricted shares of common stock to Knight upon conversion of 2,162 shares of Series A Preferred Stock.
2023	The United States Patent and Trademark Office (USPTO) allowed the first COVID-19 patent for Tafenoquine.
2024-03-01	Initiated a pilot study of Tafenoquine for treatment of canine babesiosis in the United States under a sponsored research program with North Carolina State University College of Veterinary Medicine.
2024-05-01	Signed a research and collaboration agreement with North Carolina State University College of Veterinary Medicine to screen archived blood samples for Babesia spp.
2024-06-25	First patient randomized in Trial 1 (randomized, placebo-controlled evaluation of Tafenoquine in hospitalized babesiosis patients).
2024-07-12	Entered into an At-the-Market Issuance Sales Agreement (ATM Agreement) with WallachBeth Capital LLC.
2024-07-16	Effective date of shareholder approval to increase the number of shares authorized under the 2022 Plan.
2024-07-16	Granted 504 fully vested, non-qualified options to directors Stephen Toovey, Charles Allen, Paul Field, and Cheryl Xu at an exercise price of $318.00 per share.
2024-07-16	Granted 12,334 options to Geoff Dow, Tyrone Miller, and Bryan Smith at an exercise price of $60.00 per share.
2024-07-18	Shelf registration statement on Form S-3 (Registration No. 333-280796) was declared effective by the SEC.
2024-07-19	Commencement of sales in the ATM Offering.
2024-07-22	Filed an amendment to the prospectus supplement to increase the ATM Offering amount to $1,774,640.
2024-07-24	Filed a second amendment to the prospectus supplement to increase the ATM Offering amount to $1,890,705.
2024-07-26	Filed a third amendment to the prospectus supplement to increase the ATM Offering amount to $2,190,416.
2024-08-02	Filed a fourth amendment to the prospectus supplement to increase the ATM Offering amount to $2,295,192.
2024-08-02	End of sales in the ATM Offering, with a total of 135,568 shares sold for gross proceeds of $1,994,583.
2024-08-30	Engagement Agreement dated with H.C. Wainwright & Co., LLC.
2024-09-04	Issued 579,711 pre-funded warrants, Series A Warrants, and Series B Warrants to investors in a private offering.
2024-09-26	Granted 4,167 options to Kristen Landon, Chief Commercial Officer.
2024-10-01	From October 2024 to January 2025, issued 579,711 shares of common stock upon exercise of pre-funded warrants from the September 2025 private placement.
2025-01-02	Granted 120,000 options to Geoff Dow (CEO) and Tyrone Miller (CFO).
2025-01-08	Announced IRB approval of a Phase II clinical study (NCT06656351) to evaluate Tafenoquine for chronic babesiosis.
2025-01-08	Announced the first patient enrollment in NCT06478641, an expanded access clinical study for persistent babesiosis.
2025-01-28	Entered into a securities purchase agreement for the January 2025 Registered Direct Offering.
2025-01-30	The January 2025 Offering closed, with net proceeds of approximately $804,346.
2025-02-05	Entered into a securities purchase agreement for the February 2025 Registered Direct Offering.
2025-02-06	The February 2025 Offering closed, with net proceeds of $908,627.
2025-02-01	FDA authorized the importation of Kodatef from Australia to cover potential future disruption of Arakoda in the U.S. market.
2025-02-24	Effected a reverse stock split of common stock at a ratio of 1-for-5.
2025-03-17	The ARAKODA commercial pilot program commenced.
2025-03-24	Entered into a subsequent Option Agreement with FSURF for castanospermine purification and COVID-19 treatment (12-month option).
2025-03-24	Entered into a subsequent Option Agreement with FSURF for alpha glucosidase inhibitors and Zika treatment (12-month option).
2025-03-27	Filed Annual Report on Form 10-K for the year ended December 31, 2024.
2025-03-31	Financial capitalization data as of this date.
2025-04-02	Registration statement (Selling Shareholder S-1) for February 2025 shares and warrants declared effective.
2025-04-03	Entered into an Agreement with Yale University for an exclusive license to patents related to babesiosis treatment using Tafenoquine.
2025-04-04	Entered into an Option Agreement with FSURF for large scale purification of castanospermine (12-month option).
2025-04-09	Filed Current Report on Form 8-K.
2025-05-15	Filed Quarterly Report on Form 10-Q for the three months ended March 31, 2025.
2025-07-02	Last reported sale price of common stock on The Nasdaq Capital Market was $2.455 per share.
2025-07-02	1,472,891 shares of common stock issued and outstanding.
2025-07-03	1,472,891 shares of common stock issued and outstanding.
2025-07-07	Registration Statement on Form S-1 filed with the U.S. Securities and Exchange Commission.
2025-07-14	Anticipated delivery date of securities against payment for the current offering.
2025-09-30	Assumed date by which a minimum of 24 patients are enrolled in Trial 1 for interim analysis.
2026-01-31	Earliest possible date that data would be available from the interim analysis of Trial 1.
2026-03-31	Expected fruition of results from one or more babesiosis studies in the first quarter of 2026.
2026-09-01	Earliest possible initiation date for the pediatric and adolescent malaria prophylaxis study.
2033-07-12	Royalty payment to Knight Therapeutics Inc. ends or upon full conversion/redemption of Series A Preferred Stock.
2035	Patent expiry for Tafenoquine.

Keywords

Pharmaceuticals, Biotechnology, Infectious Diseases, Malaria, Babesiosis, Fungal Infections, Antivirals, Tafenoquine, Arakoda, Celgosivir, SEC Filing, S-1, Public Offering, Warrants, Pre-Funded Warrants, Nasdaq, Going Concern, Dilution, Clinical Trials, Drug Development, Commercialization

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.